DLA Piper advises SeaSpine Holdings Corporation in its US$101 million public offering
SeaSpine Holdings Corporation (NASDAQ: SPNE) recently completed a public offering, selling 5,175,000 shares of common stock at $19.50 per share. This includes 675,000 shares purchased through the underwriters' option. The offering generated approximately $101 million before underwriting discounts and commissions. SeaSpine specializes in surgical solutions for spinal disorders, providing a variety of orthobiologics and spinal implants essential for fusion procedures. The transaction highlights SeaSpine's market presence and growth potential in the life sciences sector.
- The public offering raised approximately $101 million, enhancing financial liquidity.
- Strong market demand evidenced by the exercise of the underwriters' option for additional shares.
- Dilution risk for existing shareholders due to the issuance of new shares.
NEW YORK, May 5, 2021 /PRNewswire/ -- DLA Piper represented SeaSpine Holdings Corporation (NASDAQ: SPNE) in its recent public offering of 5,175,000 shares of its common stock at a price of
SeaSpine is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine.
"We were thrilled to assist SeaSpine with this public offering, which demonstrated the strength of our life sciences capital markets capabilities and ability to facilitate complex transactions and bring value to our clients," said Michael Kagnoff, the DLA Piper partner who led the firm's deal team.
In addition to Kagnoff, the DLA Piper team advising SeaSpine included partner Patrick O'Malley and associate Zamzama Azizi (all of San Diego).
DLA Piper's global capital markets team represents issuers and underwriters in registered and unregistered equity, equity-linked and debt capital markets transactions, including initial public offerings, follow-on equity offerings, equity-linked securities offerings, and offerings of investments grade and high-yield debt securities.
DLA Piper advises on all aspects of the life sciences sector, combining subject matter experience with considerable knowledge of the scientific, medical, regulatory, commercial and enforcement environments facing biopharmaceutical, medical device, research and diagnostics clients. Recognizing that clients' needs vary, the firm rapidly organizes and customizes client service teams, whether for a large pharmaceutical company, a mid-sized medical device client or a development-stage biotech company.
About DLA Piper
DLA Piper is a global law firm with lawyers located in more than 40 countries throughout the Americas, Europe, the Middle East, Africa and Asia Pacific, positioning us to help clients with their legal needs around the world. In certain jurisdictions, this information may be considered attorney advertising. dlapiper.com
View original content:http://www.prnewswire.com/news-releases/dla-piper-advises-seaspine-holdings-corporation-in-its-us101-million-public-offering-301284630.html
SOURCE DLA Piper
FAQ
What was the total amount raised by SeaSpine's public offering?
How many shares did SeaSpine offer in its recent public offering?
What was the price per share in SeaSpine's public offering?
What is SeaSpine's focus in the medical technology sector?
What was the impact of the public offering on SeaSpine's shareholders?
